Overview

NAC for Attenuation of COVID-19 Symptomatology

Status:
Not yet recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to determine whether oral NAC is effective at attenuating COVID-19 disease symptom severity and duration of symptoms.
Phase:
Phase 2
Details
Lead Sponsor:
Cambridge Health Alliance
Collaborators:
Alturix
The Thoracic Foundation
Treatments:
Acetylcysteine
N-monoacetylcystine